Market Closed -
Nasdaq
16:00:00 2024-05-15 EDT
5-day change
1st Jan Change
4.67
USD
+0.86%
+0.65%
+9.62%
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 2500 Index
June 23, 2023 at 12:00 am
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 2500 Index
Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-07
CI
Transcript : Inozyme Pharma, Inc. - Special Call
04-08
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1
Deficiency
04-08
CI
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency
03-26
CI
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-12
CI
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-07
CI
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions
23-10-10
CI
Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency
23-09-26
CI
Inozyme Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-08
CI
Insider Buy: Inozyme Pharma
23-08-04
MT
Sector Update: Health Care Stocks Rising Late Friday
23-07-28
MT
Sector Update: Health Care
23-07-28
MT
Inozyme Pharma Prices $60 Million Share Offering
23-07-28
MT
Sector Update: Health Care Stocks Declining Late Wednesday
23-07-26
MT
Sector Update: Health Care Stocks Falling Wednesday Afternoon
23-07-26
MT
Sector Update: Health Care
23-07-26
MT
Inozyme Pharma Updates INZ-701 Development Plan After Meetings With US, EU Regulators; Shares Drop
23-07-26
MT
Transcript : Inozyme Pharma, Inc. - Special Call
23-07-26
Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
23-07-26
CI
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701
23-06-27
CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell Small Cap Comp Value Index
23-06-23
CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 3000 Index
23-06-23
CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 3000E Index
23-06-23
CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell Small Cap Completeness Index
23-06-23
CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 2500 Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Companyâs lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
More about the company
Last Close Price
4.67
USD
Average target price
20.33
USD
Spread / Average Target
+335.40%
Consensus
1st Jan change
Capi.
+9.62% 289M +29.77% 49.46B +1.00% 42.58B +50.35% 42.49B -5.26% 29.09B +13.68% 26.61B -22.99% 18.64B +8.22% 13.16B +32.41% 12.55B -1.62% 11.98B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**